Skip to content

Pharminent

cropped-banner_frontpage_2026-07-11-2.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Commercial
  • Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool
  • Commercial

Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool

BioPharma Dive

Some 1,390 Foundayo prescriptions were written in two days, according to analysts.

CommercialMetabolic & GLP-1Read full story

pharminent April 17, 2026 (Last updated: April 17, 2026)

BioPharma Dive

Some 1,390 Foundayo prescriptions were written in two days, according to analysts.

CommercialMetabolic & GLP-1Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch
Next: Kailera makes history with record-breaking $625m IPO

Related Stories

  • Commercial

Wegovy pill launches in UK as first daily oral GLP1 for weight management

pharminent July 6, 2026
  • Commercial

Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval

pharminent June 26, 2026
  • Commercial

Lilly launches its LillyDirect sales channel in the UK

pharminent June 25, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.